Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Objective Response Rate — .85 proportion of patients

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value

Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: Overall Response Rate — 81.8 Percentage

Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: ORR (Overall Response Rate) — 46 Percentage of Participants

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Total Number of Adverse Events. — 2 Adverse events

Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044

Primary: Progression-Free Survival (PFS) at 2 Years — 82; 81 percentage of participants

Primary: Progression-free Survival — 72 Percent

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Event-free Survival — 16 Participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants